We have established a systematic high-throughput screen for genes that cause cell death specifically in transformed tumor cells. In a first round of screening, cDNAs that induce apoptosis in a transformed human cell line are detected. Positive genes are subsequently tested in a synthetic lethal screen in normal cells versus their isogenic counterparts that have been transformed by a particular oncogene. In this way, the organic cation transporter-like 3 (ORCTL3) gene was found to be inactive in normal rat kidney (NRK) cells, but to induce apoptosis in NRK cells transformed by oncogenic H-ras. ORCTL3 also causes cell death in v-srctransformed cells and in various human tumor cell lines but not in normal cells or untransformed cell lines. Although ORCTL3 is a member of the organic cation transporter gene family, our data indicate that this gene induces apoptosis independently of its putative transporter activity. Rather, various lines of evidence suggest that ORCTL3 brings about apoptosis by an endoplasmic reticulum stress-mediated mechanism. Finally, we detected ORCTL3 to be downregulated in human kidney tumors.
The finding that various cytostatic drugs elicit an apoptotic response in cancer cells 1 has generated great interest in the application of this cellular phenomenon against tumor cells. Underlying these efforts is the hope that the manifold changes inflicted on cancer cells during the transformation process and the resultant aberrant signaling circuits render them sensitive to specific pro-apoptotic stimuli that spare normal cells. Several genes have been found to induce the cellular suicide program specifically in transformed tumor cells. Among them are the viral genes E4orf4 2 and apoptin, 3 and also, importantly, cellular genes such as mda-7/IL-24, 4 Hamlet, 5 par-4, 6 and TRAIL. 7 For none of these genes is it known how exactly they exert their tumor-specific effect. Nevertheless, these discoveries established that the genome contains sequences that act against malignant transformation by inducing apoptosis. So far, tumorspecific apoptosis genes have been discovered only fortuitously. Moreover, research conducted to date has not addressed the genetic changes of the transformation process that activate these genes as apoptosis inducers. We speculated that additional tumor-specific apoptosis genes exist in the genome that target cellular changes caused by specific oncogenes. Hence, we set up a genome-wide screen to systematically discover pro-apoptotic genes that are activated by the H-ras oncogene. We present here ORCTL3 as the first tumor-specific pro-apoptotic gene from this screen.
Results
Screen for tumor-specific apoptosis-inducing genes. We have used our recently described RISCI screen 8 to search for pro-apoptotic cDNA plasmids in the kidney cell line HEK293T. These cells display characteristic features of tumor cells such as growth in soft agar and tumor formation in nude mice. 9 Our screen 10 has so far led to 112 apoptosis genes out of a total of 150 000 clones or B60% of one normalized cDNA library. [11] [12] [13] [14] [15] All genes that scored positive in this assay were subsequently transfected in parallel in H-ras-transfected normal rat kidney (NRK) cells and in their untransformed, parental cells. This synthetic lethal screen allowed us to conduct the experiments in a defined isogenic background (Figure 1a ). By using NRK cells, we remained in a renal cell system with the cDNAs taken from the kidney and with the first indicator cell line (HEK293T) also from this organ. We chose H-ras as this gene is activated in about 20% of human tumors 16 and imposes resistance to apoptosis, 17 a hallmark of tumor cells. 18 Moreover, H-ras elicits the same malignant changes in NRK cells as observed with HEK293 cells, 19 suggesting that it causes common signaling modifications. Phase contrast microscopy revealed the typical irregular growth pattern of transformed cells in contrast to wild-type (WT) NRK cells and an immunoblot produced a prominent signal generated by the transfected H-ras gene (Supplementary Figure 1A and B ). This established these cells as a bona fide transformation system. A total of 44 genes from the primary screen remained active for apoptosis induction in H-ras-transformed NRK cells. In accordance with the cell death inhibitory effect of H-ras, several genes were more potent apoptosis inducers in WT NRK cells (not shown). However, one clone, later identified as ORCTL3 (see below), was active for apoptosis induction in the H-ras-transformed cells but did not cause detectable apoptosis in WT NRK cells. Visual inspection of cells marked with a co-transfected GFP construct showed that this gene induced cell shrinkage and membrane blebbing, both typical features of apoptotic cells (Figure 1b and c). Other apoptosis genes from the screen, including a number of transporters and plasma membrane-bound proteins, did not score positive in this assay. A quantitative assay specific for apoptotic DNA cleavage and cell death inhibition by the pan-caspase inhibitor zVAD confirmed apoptosis induction Figure 1 ORCTL3 specifically induces apoptosis in H-ras-transformed cells compared to wild-type (WT) NRK cells. (a) Outline of the screen for tumor-specific apoptosis genes. Aliquots containing single bacteria clones were inoculated in wells of 96-well blocks in LB medium, and the plasmid DNA was isolated using silica oxide. After calcium phosphate transfections in 96-well plates, an enzymatic readout for apoptosis detection was employed. The plasmids of those genes that scored positive in this assay were then examined in parallel transfections in WT NRK cells and NRK cells transformed by the H-ras oncogene. To this end the transfection mixes were equally split and added to the cells. (b) Specific generation of the apoptosis phenotype by ORCTL3 in H-ras-transformed cells. Transfection mixes with ORCTL3 (or luciferase) and GFP expression plasmids were equally distributed between WT and H-ras-transformed NRK cells. Fluorescence pictures were taken after 24 h. (c) Quantification of the apoptosis induction by ORCTL3 in NRK WT and NRK H-ras cells. At 24 h after co-transfecting an expression vector for GFP and ORCTL3 (or luciferase), apoptosis was assessed by phenotype quantification. Shown are the means and the standard deviation of three independent experiments (Po0.01 in H-ras NRK cells, nonsignificant in WT NRK cells). (d) Quantification of apoptosis by ORCTL3 with an ELISA against DNA fragments. At 24 h after the transfection of expression constructs for ORCTL-3 or luciferase, an ELISA was performed that detects DNA fragments generated during apoptosis (Po0.01 in H-ras NRK cells, P-value nonsignificant in WT NRK cells, n ¼ 3). (e) Reduction of apoptosis by the pan-caspase inhibitor zVAD. NRK H-ras cells were transfected with the indicated plasmids together with an expression construct for GFP. After the transfection, 25 mM zVAD was added to the cells. Apoptosis was quantified after 24 h by phenotype inspection (Po0.01, n ¼ 3)
( Figure 1d and e). Sequencing identified the gene as fulllength ORCTL3/SLC22A13, which was originally determined through large-scale sequencing of genomic DNA. 20 On the basis of its sequence homology, it is a member of the organic cation transporter (OCT) family 21 that mediates the absorption and secretion of many structurally diverse cations. 21 To date, however, ORCTL3 is one of the least studied OCTs and only recently it has been shown to be a urate and high-affinity nicotinate transporter. 22 Characterization of cell death by ORCTL3. We performed a structure-function analysis by testing progressive deletions of ORCTL3 for apoptosis induction. Figure 2a reveals that the C-terminal half of the protein can be deleted without substantially disrupting the apoptosis potential of ORCTL3. This indicated that ORCTL3 does not require its putative transporter activity for apoptosis induction.
To determine the specificity of the signal elicited by ORCTL3, we transfected SLC22A1 and SLC22A12, two related gene family members of the OCT family, but have not observed any effect on apoptosis ( Figure 2b ). Even when we doubled the amount of plasmid, we did not detect an apoptotic response (not shown). Transient transfection and activation of H-ras, which also occurs in normal cells, is not sufficient for ORCTL3 to induce apoptosis ( Figure 2c ). As our sequencing of the endogenous H-ras gene (variants 1, 2, 3) from HEK293T cells did not reveal activating mutations at codons 12, 13 or 61 (data not shown), we speculated that apoptosis induction by ORCTL3 is not limited to H-rastransformed cells. Hence, we assessed cell death by ORCTL3 in NRK cells transformed by v-src (Supplementary Figure 1C and D) and likewise observed apoptosis in these cells ( Figure  2d and e). We then compared the ability of ORCTL3 to induce apoptosis in a number of transformed tumor cells and untransformed cells. Figure 3a shows that ORCTL3 can induce apoptosis in the human tumorigenic kidney cell line HEK293T, the human cervical HeLa cell line and in human LnCap and PC3 prostate cancer cells. ORCTL3 is also able to cause apoptosis in transformed baby hamster kidney (BHK) cells, but not in untransformed Madin-Darby canine kidney (MDCK) cells ( Figure 3b ). Moreover, ORCTL3 was likewise inactive for apoptosis induction in human umbilical vein To more closely relate the expression of ORCTL3 with the apoptotic response of the cells, we generated a C-terminal ECFP fusion protein of ORCTL3 and tested its apoptosis induction in HeLa cells, HEK293T cells, HUVEC and in WT and ras-transformed NRK cells. Figure 4a shows that only untransformed HUVEC and WT NRK cells did not succumb to apoptosis when this construct was transfected (see also Supplementary Figure 2 ). We also studied the expression level of the ORCTL3 fusion protein in the various cell types by measuring its fluorescence signal and normalizing this to the respective transfection efficiency. As Figure 4b reveals, the level of the ORCTL3-ECFP signal was comparable in all the cells. We also assayed the expression level of the endogenous ORCTL3 and compared this to the transfected ORCTL3 fusion protein in WT and ras-transformed NRK cells. Figure 4c shows the increase of the signal as detected in a semiquantitative RT-PCR.
Role of endoplasmic reticulum stress for ORCTL3 apoptosis induction. We studied the spatial distribution of the ECFP fusion protein of ORCTL3 with specific staining of organelles in HeLa cells. This fusion protein was found at the endoplasmic reticulum (ER), the Golgi and the plasma membrane ( Figure 5 ), indicating that the ORCTL3 protein transport conforms to the known internal route of plasma membrane proteins. Importantly, we have not found an overlap with the signal from the mitochondria-specific probe, MitoTracker Red CMXRos. Because another tumor-specific apoptosis inducer the viral apoptin protein is differentially localized in normal versus tumor cells, 3 we determined the localization of the ORCTL3-ECFP fusion protein in WT and ras-transformed NRK cells but found no difference in its cellular locale between these cell types (not shown). As ORCTL3 could cause cell death at intracellular sites during transit, we applied the pan-caspase inhibitor zVAD to block apoptosis and expected that those cells that accrue contain ORCTL3 at the relevant locale for apoptosis induction. Figure 6a shows that upon cell death inhibition the percentage of cells with a prominent intracellular accumulation of the ORCTL3-ECFP protein increased whereas the percentage of apoptotic cells decreased proportionally (see also Supplementary Figure 3 ). Hence, we speculated that ORCTL3 exerts its apoptosis activity at the ER or the Golgi. A fusion construct with an ER retention signal at the C terminus of ORCTL3 led to higher apoptosis induction than WT ORCTL3, whereas a fusion construct with a Golgi retention signal caused less apoptosis ( Figure 6b ). Consequently, we speculated that ORCTL3 is inducing the signal for apoptosis at the ER, an organelle with a wellrecognized function in apoptosis. In support of this ORCTL3 as a tumor-specific apoptosis inducer S Irshad et al hypothesis, we found that co-transfection of the ER stress inhibitor BiP/GRP78 caused a reduction in apoptosis ( Figure 6c ). ER stress is a complex cellular response that leads to the upregulation of both pro-and anti-apoptotic genes. We determined the protein levels of the ER stress factors ATF4/CREB2 as a pro-apoptotic protein, and BiP as an anti-apoptotic protein in ORCTL3-transfected cells. In these experiments, we used the ER stressors tunicamycin or ionomycin as controls whose apoptotic effects are influenced by the expression level of BiP. 23, 24 Our results show that in cells that undergo apoptosis upon ORCTL3 expression (HeLa and HEK293T cells), ATF4 was upregulated to an extent comparable with control-treated cells. BiP, on the other hand, did not increase when compared to tunicamycin-or ionomycin-treated cells (Figure 6d and e). In contrast, HUVECs that do not succumb to apoptosis upon ORCTL3 transfection failed to show any signs of ER stress, with neither BiP nor ATF4 being upregulated (Figure 6f ). Transfection efficiency in these experiments, as determined by GFP-transfected cells, was 40% in HeLa cells, 60% in HEK293T cells and 65% in HUVEC (not shown). Treatment with the ER stress inducer tunicamycin could also increase BiP in HUVEC (Figure 6f ) and did not indicate that HeLa cells are more susceptible to ER stress than HUVEC ( Supplementary Figure 4) .
ORCTL3 is downregulated in human kidney tumors. A broader function of ORCTL3 during tumorigenesis was suggested as deletions in its chromosomal locus 3p21.3 have been linked to carcinomas of various organs. 25, 26 We found microarray data with significant P-values from the Oncomine database indicating that this gene is repressed in tumors of the adrenal gland and the bladder (not shown). Importantly, using the Cancer Profiling Array, a blot that compares tumor versus normal tissue of the same patients, we detected that ORCTL3 is significantly downregulated in human renal carcinomas (Figure 7 ).
Discussion
In this study, we have presented an assay to systematically search the genome for genes that induce apoptosis specifically in tumor cells. This is achieved by two consecutive assays that culminate in a synthetic lethal screen, which directly compares the activities of genes in cells transformed by specific oncogenes versus their normal counterparts ( Figure 1a ). The concept of synthetic lethality has recently gained wide recognition as a useful tool in cancer research. 27 Its integration into our assay has the potential to reveal proapoptotic signaling pathways specific for certain oncogenes, such as H-ras. We observed that ORCTL3, our first isolate from this screen, is likewise active in H-ras-and v-srctransformed cells, and in several other cell lines of different (Figures 2 and 3 ). This suggests that at least one aspect of the transformation by H-ras is shared with other tumor cells and that this exposes cells to particular pro-apoptotic signaling pathways, one of which is targeted by ORCTL3.
With ORCTL3 being a member of the transporter gene superfamily, we expected its putative transporter activity to be involved in its ability to induce apoptosis. On the basis of our deletion studies (Figure 2a ), however, we do not believe that it is working directly as a transporter for apoptosis induction. Our data indicate that ORCTL3 causes ER stress in cells undergoing apoptosis. ER stress is induced by the accumulation of unfolded proteins within the ER, but also by numerous additional signals that lead to the disruption of ER function. 28 It is believed that ER stress first triggers an anti-apoptotic response in the cells with upregulation of chaperones such as BiP. However, if the stimulus persists, this is then followed by a pro-apoptotic reaction. The signal induced by ORCTL3 seems to lead to an unconventional ER stress response. Although BiP is normally strongly upregulated as part of the anti-apoptotic response during ER stress, under the conditions used we have not observed an increase of the BiP protein upon ORCTL3 transfection comparable to tunicamycin-treatment. In contrast, the pro-apoptotic ATF4 transcription factor is upregulated upon ORCTL3 overexpression ( Figure 6) . A reduced BiP response despite ER stress induction is not without precedent. It was found in WEHI7.1 cells upon thapsigargin treatment, which led to efficient apoptosis induction. 29 As specific upregulation of BiP by co-transfection can inhibit ORCTL3-induced apoptosis (Figure 6c ), the reduced increase of BiP could be an important aspect of ORCTL3's activity in long-established tumor cell lines, which can be expected to have accumulated numerous mutations that thwart cell death and support the anti-apoptotic response during ER stress. This per se, however, is unlikely to explain the tumor-specific signal of ORCTL3 as BiP knockout has been shown to cause apoptosis in untransformed cells. 30 Our data indicate that apoptosis upon ER stress by tunicamycin is not more efficiently induced in HeLa cells compared to HUVEC ( Supplementary Figure 4) , which argues against ORCTL3 exploiting a general difference in the sensitivity to ER stress in normal and transformed cells. Hence, we believe that ORCTL3 induces a signal that is interpreted as pro-apoptotic ER stress in tumor cells but not in normal cells. Interestingly, another tumor-specific gene, mda-7/IL-24, has recently been implicated in ER stress as it localizes to the ER and interacts with BiP. 31 Future studies will need to address the precise differences in signaling pathways between normal and tumor cells, which allow ORCTL3 to induce tumor-specific ER stress.
ORCTL3 seems to be involved in tumorigenesis as indicated by its downregulation in renal tumors (Figure 7) . It may also be downregulated in additional cancers as it is expressed at low levels also in tissues other than the kidney, 20 but our commercial filter blot was not sensitive enough to detect this. We assume that even at its endogenous expression level this gene can be activated for cell destruction during tumorigenesis and that its downregulation allows for continued survival of cancer cells. This qualifies ORCTL3 as a candidate for a tumor suppressor gene and demonstrates that our screen can also serve as a novel tool to determine such activities.
How many genes with a tumor-specific activity can be expected? The analysis so far revealed one cDNA library as tumor specific. Although our current screen is still limited to cellular genes, viral DNAs, cDNA fragments encoding protein domains or other genetic means such as shRNAs could potentially expand the positive hits in this screen. Additional screens could target oncogenes that, in contrast to H-ras, do not exert an anti-apoptotic effect or genetic changes specific for HEK293 cells such as the viral genes E1A and E1B. 32 Moreover, because tumorigenesis is a multistep process, one could introduce additional genetic lesions in already transformed cells against which the synthetic lethal screen is directed. Hence, our approach could be of wider use to uncover signals that specifically induce the demise of transformed cells.
Materials and Methods
Materials. The pan-caspase inhibitor zVAD-fmk was purchased from Enzyme Systems Products. Cross-linked polyethylenimine was a kind gift from Dr. Klibanov, Cambridge, USA. The ER-Tracker Blue-White DPX, BODIPY TR C 5 Ceramide Golgi-tracker dye, MitoTracker Red CMXRos, and Vybrant Apotosis Assay Kit#4 were from Molecular Probes, Invitrogen. All fine chemicals were from Sigma Inc. unless specified otherwise. The clones for SLC22A and SLC22A12 were obtained from the IMAGE clone collection through the GeneService (Cambridge, UK). The t-test was used to assess the statistical significance of the data. If P40.1 we state that the P-value was nonsignificant. Experiments with n ¼ 3 were repeated at least once and one representative result is shown.
Cell culture. HEK293T, 33 HeLa (ATCC no.: CCL-2) and NRK cells (CRL-6509) were cultured in DMEM (Sigma) supplemented with 5% (HEK293T, NRK) or 10% (HeLa) FCS (Sigma). HUVEC and RPT cells (Lonza, Basel, Switzerland) were grown in Endothelial Growth Medium Bulletkit (Lonza) and Renal Epithelial Growth Medium Bulletkit (Lonza), respectively. HUVEC were transfected using HUVEC Nucleofector kit (Amaxa), whereas RPT cells were transfected using basic nucleofector kit for Primary Mammalian Epithelial Cells (Amaxa). HEK293T, HeLa cells and NRK cells were transfected with Superfect (Qiagen), Effectene (Qiagen) and Fugene (Roche, Mannheim, Germany), respectively, according to manufacturer's instructions. For stable transfections, NRK cells were selected with 500 mg/ml G418 (Calbiochem). PC3 (CRL-1435) were grown in RPMI 10% FCS and transfected with IBAfect/MA Lipofection Enhancer (Promokine, Heidelberg, Germany). BHK cells (CCL-10) were grown in DMEM, 5% FCS and transfected using calcium phosphate. LnCap (CRL-1740) were grown in RPMI, 10% FCS and transfected with Lipofectamine 2000 (Invitrogen). MDCK (CCL-34) were maintained in DMEM, 10% FCS and transfected using cross-linked polyethylenimine. 34 Fluorescent imaging. HeLa cells were grown on coverslips for 24 h, transfected with an ORCTL3-ECFP expression vector and incubated for another 24 h with zVAD to avoid secondary effects due to apoptosis induction. For nuclear staining, cells were washed twice in PBS and incubated in 4% formaldehyde for 20 min at room temperature. Cells were then incubated in 4 0 ,6-diamidino-2phenylindole (DAPI) solution for 1 h in the dark at room temperature. Before the other organelle stainings, cells were washed in 1 Â PBS and then incubated in 600 nM ER-Tracker Blue-White DPX, 5 mM BODIPY TR C 5 Ceramide Golgi-tracker dye or 40 nM MitoTracker Red CMXRos. Cells were rinsed three times in ice-cold growth medium and incubated in fresh full growth medium at 371C for a further 30 min. Cells were then washed twice in 1 Â PBS and incubated for 20 min at room temperature with 4% formaldehyde. Coverslips were mounted on microscope slides. Fluorescence was detected with FITC, DAPI and TRITC filters of a fluorescent microscope (Zeiss) at magnification Â 63, using a Zeiss Axiovert camera. WT and ras-transformed NRK cells were stained using the same protocol as for HeLa cells.
DNA constructs. The H-ras and the v-src construct that were used to generate stably transfected NRK cells have been described. 35 For the deletion mutants suitable primers were used with the Expand Long Template PCR System (Roche Diagnostics), which has proofreading activity. Expression plasmids were constructed by inserting the cDNAs into the vector pcDNA3 (Invitrogen). All PCR products were sequenced to verify the correct sequence. BiP was amplified using suitable primers with the Phusion high-fidelity DNA polymerase (Finnzymes) and subcloned into the pcDNA3 vector. Fusion constructs of ORCTL3 in the mammalian expression vector pcDNA3 were generated with eight-amino-acid ER retention sequence 36 and Golgi retention signal 37 derived from the G 1 protein of UUK virus, which was a kind gift from Dr. Pettersson (Karolinska Institute, Sweden). ORCTL3-ECFP was generated as a fusion construct with a pcDNA3 vector backbone. Plasmid DNA was isolated using Qiagen maxi-prep kit according to the manufacturer's instructions. The ORCTL3 sequence was identified with the IMAGE 4609915 cDNA clone.
Apoptosis detection. Apoptosis was quantified by four different methods. The first involved determining the ratio of transfected (GFP positive) and phenotypically apoptotic cells (displaying volume loss and/or membrane blebbing) in relation to all GFP-positive and therefore transfected cells. At least 300 cells were counted in each independent experiment. The second method involved measuring nucleosomal DNA fragments by an ELISA kit (Roche Diagnostics). The third method utilized sub-G 1 DNA content determined by flow cytometry in transfected cells as described. 11 Finally, apoptosis in human renal proximal tubular epithelial cells (RPT) was quantified using the Vybrant Apotosis Assay Kit#4 (Molecular Probes, Invitrogen) and analyzed by flow cytometry according to the manufacturer's instructions.
Immunoblotting. Whole cell lysates were isolated using RIPA buffer supplemented with protease inhibitors (Complete Mini; Roche). Each sample (40 mg) was separated in a 10 or 12% SDS-PAGE gel and electrophoretically transferred onto polyvinylidene or nitrocellulose membranes (Amersham Pharmacia). The membranes were blocked with 5% nonfat dry milk powder in 0.1% Tween-20 (Sigma) and incubated with antibodies against H-ras (Santa Cruz), src (Oncogene), ATF4/CREB2 (C-20; Santa Cruz), BiP/GRP78 (N-20; Santa Cruz) or b-actin (Sigma). The membranes were then washed three times in 0.1% Tween/ 1 Â PBS and incubated in appropriate secondary antibodies. After additional washes, the reactions were developed by enhanced chemiluminescence reagents (Pierce or Amersham Biosciences). Quantification of ORCTL3 expression level by fluorescence. The plasmid pCDNA3-ORCTL3-ECFP was transfected in duplicates in 24-well plates with the various cells lines. Each experiment was performed twice. At 24 h after the transfection, the FLUOstar OPTIMA plate reader (BMG Labtech) measured the fluorescence intensity emitted by each well at 520 nm. Then the cells from the same well were analyzed by flow cytometry. The FL1 channel was used to detect the number of cells expressing ORCTL3-ECFP. The fluorescence intensity measured by the plate reader was then normalized to the percentage of transfected cells determined by flow cytometry.
Quantification of ORCTL3 expression levels by reverse transcription PCR. WT and ras-transformed NRK cells were transfected (JetPI Polyplus) or not by the following vectors: pCDNA3-ORCTL3-ECFP or pLantern-GFP, 24 h before the extraction of the RNA using TRIzol reagent (Invitrogen). The RNA was applied directly to the Titan One Tube RT-PCR kits (Roche Applied Sciences) using AMV reverse transcriptase for first strand cDNA synthesis and the Expand High-Fidelity enzyme consisting of Taq DNA plymerase and Tgo DNA polymerase for amplification of the cDNAs by PCR. All reactions were carried out following the procedures described by the manufacturers. ORCTL3 expression was analyzed in a 1% agarose gel, after amplification of a 477-nt fragment with the following oligonucleotides: 5 0 -CCAGCTTTGAGCTCTA-3 0 and 5 0 -CTGTCCACAAACCAGACA-3 0 . The b-actin gene was amplified in parallel with the following oligonucleotides: 5 0 -GCTCGTCGTCGACAACGGCTC-3 0 and 5 0 -CAAACATGATCTGGGTCATCT-3 0 and used as a loading control.
Blot array hybridization. For hybridization of the Matched Tumor/Normal Profiling Array (Clontech), the coding sequence of ORCTL3 was labeled with 5 0 -[a 32 P]-dCTP using the RediPrime random prime labeling kit (Amersham) with 200 ng plasmid and 50 mCi [ 32 P]dCTP. The blot was prehybridized for 3 h at 651C in 40 ml of hybridization buffer (6 Â SSC, 5 Â Denhardt's reagent, 0.5% SDS, 0.1 mg/ml salmon sperm DNA), then 10 ml of a 50% dextran sulfate solution and finally the labeled probe (approximately 3 Â 10 7 c.p.m.) was added to the hybridization solution and incubated at 621C for 6 h. The blot was washed with buffer 1 (2 Â SSC, 0.5% SDS), buffer 2 (1 Â SSC, 0.5% SDS) and buffer 3 (0.5 Â SSC, 0.5% SDS), exposed in a BAS 2500 phosphoimager screen (Fujifilms, Heidelberg, Germany) and the signals were quantified using the Image Gauge V3.01 software.
